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to promote organizational sustainment of an 
empirically-supported behavior therapy
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Abstract 
Background: Pragmatic trials of empirically-supported behavior therapies may inform clinical and policy decisions 
concerning therapy sustainment. This retrospective trial design paper describes and discusses pragmatic features 
of a hybrid type III implementation/effectiveness trial of a contingency management (CM) intervention at an opioid 
treatment program. Prior reporting (Hartzler et al., J Subst Abuse Treat 46:429–438, 2014; Hartzler, Subst Abuse Treat 
Prev Policy 10:30, 2015) notes success in recruiting program staff for voluntary participation, durable impacts of CM 
training on staff-level outcomes, provisional setting implementation of the intervention, documentation of clinical 
effectiveness, and post-trial sustainment of CM.
Methods/design: Six pragmatic design features, and both scientific and practical bases for their inclusion in the trial, 
are presented: (1) a collaborative intervention design process, (2) voluntary recruitment of program staff for therapy 
training and implementation, (3) serial training outcome assessments, with quasi-experimental staff randomization to 
either single or multiple baseline assessment conditions, (4) designation of a 90-day period immediately after training 
in which the setting implemented the intervention on a provisional basis, (5) inclusive patient eligibility for receipt of 
the CM intervention, and (6) designation of two staff as local implementation leaders to oversee clinical/administra-
tive issues in provisional implementation.
Discussion: Each pragmatic trial design feature is argued to have contributed to sustainment of CM. Contribu-
tions implicate the building of setting proprietorship for the CM intervention, culling of internal staff expertise in its 
delivery, iterative use of assessment methods that limited setting burden, documentation of setting-specific clinical 
effectiveness, expanded penetration of CM among staff during provisional implementation, and promotion of setting 
self-reliance in the oversight of sustainable implementation procedures. It is hoped this discussion offers ideas for 
how to impact local clinical and policy decisions via effective behavior therapy dissemination.
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Background
Decades ago, the National Institute on Health [1] iden-
tified clinical trials as “the most definitive tool for eval-
uation of the applicability of clinical research” with 
precision in controlled therapy comparisons expected 
to improve the quality and cost-effectiveness of health 
services. This hope remains despite persistent debate 
among researchers, policy makers, and the treatment 
community as to where on an internal-external validity 
pendulum most useful trial designs lie. Many traditional-
ists tout the randomized controlled trial (RCT) as a gold 
standard methodology [2]. Benefits ascribed to RCTs, as 
outlined by Friedman et al. [3], are that they: (1) eliminate 
bias in patient assignment to treatments, (2) produce, in 
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theory, comparable groups to minimize potential 3rd-
variable influences, and (3) assure the validity of corre-
sponding statistical tests. Counterarguments focus on 
the poor representativeness of recruited patients and 
study settings in RCTs, as well as real-world inapplicabil-
ity of many procedures and outcomes [4]. Debates about 
trial design are further perpetuated by lack of consensus 
among systematic reviews of evidence generated by RCTs 
versus time-series and case-controlled designs [5–9].
An extension of this debate contrasts explanatory and 
pragmatic trials, dating back half a century to Schwartz 
and Lellouch’s [10] characterization of the former as test-
ing a therapy’s causal relations to its outcomes and the 
latter as addressing its implications for health services 
policy. Perceived overreliance on explanatory trials has 
prompted outcries for research with greater real-world 
applicability [11, 12]. Flay [13] was an early advocate that 
in order to address health service policy implications, 
trials must focus beyond patient outcomes to broader 
issues of therapy implementation and sustainment. This 
notion now appears prophetic, given subsequent Insti-
tute of Medicine [14] reporting of ‘research-to-practice 
gaps’ in addiction care. Frequent and continual citation of 
this report among addiction treatment researchers nearly 
two decades later underscores that there is still much 
to learn about the implementation and sustainment of 
empirically-supported behavior therapies in addiction 
care settings.
In the current funding climate, advancing the science 
of behavior therapies necessarily involves efficient evalu-
ation methods. Hybrid designs that blend traditional fea-
tures of efficacy and effectiveness trials are a suggested 
means of expediting knowledge about therapy impacts 
[15–17]. In a similar vein, Curran et  al. [18] propose a 
typology of hybrid trial designs conjointly addressing 
therapy effectiveness and implementation. This includes: 
(1) hybrid type I trials, that principally determine ther-
apy effectiveness and secondarily explore setting factors 
influencing its implementation, (2) hybrid type II trials, 
with co-primary aims to test therapy effectiveness and 
utility of implementation strategies, and (3) hybrid type 
III trials, which examine implementation strategies for 
an already empirically-validated therapy and secondarily 
evaluate resulting clinical effectiveness. Just as efficacy/
effectiveness hybrid designs efficiently test a therapy’s 
clinical impacts [17], so to should implementation/effec-
tiveness hybrid designs [18] spur expeditious insights 
into its health service policy implications.
Choices faced by behavior therapy researchers about 
trial design will be influenced by a therapy’s existing 
empirical support. With respect to trials conducted in 
addiction treatment settings, contingency management 
(CM) is comprehensively studied as a therapy wherein 
behavioral reinforcement principles shape patient treat-
ment adherence. Already a focus of 200+ published tri-
als in such settings, meta-analyses of CM note reliable 
therapeutic effects [19–21]. Further, clinical effectiveness 
is demonstrated in paired NIDA Clinical Trials Network 
studies [22, 23]. Nevertheless, optimism about CM dis-
semination is tempered by low rates of treatment com-
munity adoption [24–26], with identified sources of 
reluctance that encompass fiscal, logistical, and ideologi-
cal barriers [27, 28]. Collectively, this positions CM well 
for the conduct of Curran et al.’s [18] hybrid type III tri-
als—wherein primary units of analysis for trial outcomes 
consist of treatment sites (i.e., therapy implementation 
costs, logistical feasibility, sustainability) and their exist-
ing staff members (i.e., therapy skill, knowledge, atti-
tudes, eventual adoption).
In a CM-focused hybrid type III trial at an opioid treat-
ment program (OTP), Hartzler et al. [29] tested as imple-
mentation strategies a collaborative intervention design 
process, active learning strategies to cull staff delivery 
skills and adoption readiness in CM training, and desig-
nation of two OTP staff as local implementation leaders. 
As previously reported [29, 30], trial findings include: 
(1) effective recruitment of 80+ % of OTP staff for vol-
untary participation, (2) robust, durable training impacts 
on CM delivery skill (d =  2.43) and adoption readiness 
(d =  .88), 3) 100 % penetration among CM-trained staff 
during a 90-day period in which implementation by the 
setting was conducted on a provisional basis, (4) medium 
effects on targeted patient behaviors (d =  .46–.53, rela-
tive to historical control patients), (5) qualitative impres-
sions of CM affordability and compatibility among OTP 
management at trial conclusion, and (6) post-trial set-
ting report of continuous two-year sustainment of CM 
among routine service provisions. Collective outcomes 
suggest that pragmatic design features of this single-site 
trial may offer useful ideas for how to impact local clini-
cal and policy decisions via effective behavior therapy 
dissemination.
Johnson et al. [31] offer a musical analogy for the chal-
lenges of pragmatic trial design, likening the rigorous 
structure of traditional treatment research to classical 
music and the fluidity of clinical practice to improvisa-
tional jazz. To extend the analogy, a well-conceived prag-
matic trial will include design features that harmonize 
these musical styles so findings prompt data-informed, 
sustainable services. This paper—authored by a univer-
sity-based investigator (BH), the OTP director (TRJ), an 
implementation leader (KMP), and a managerial staff 
member (MC) in the aforementioned CM trial—takes a 
retrospective view in describing six pragmatic design fea-
tures outlined in Table 1. The lead author (in his capac-
ity as a behavior therapy dissemination researcher) 
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embraced a role of therapy purveyor in seeking to dis-
seminate CM to this community setting, insofar as he 
conceived the trial design, provided organizational con-
sultation and training of staff, evaluated clinical impacts 
of therapy implementation, and assessed OTP decisions 
about its eventual sustainment. Herein, these trial design 
features are detailed, followed by discussion of underly-
ing scientific and practical rationales for their inclusion 
in the trial as well as perceived influence on trial out-
comes and eventual sustainment of the CM intervention 
in this OTP setting.
Methods/design
Ethics, consent, and permissions
This implementation/effectiveness hybrid type III trial 
was conducted with full approval of the University of 
Washington Institutional Review Board. Participat-
ing OTP staff members provided informed consent in 
writing prior to their voluntary involvement in any trial 
activities.
Pragmatic trial design feature #1: Collaborative 
intervention design
The intent was to create a clinically-useful intervention 
matched to OTP implementation capacity (i.e., operat-
ing budget, staffing resources), for which community 
treatment perspectives have proven salient in past CM 
dissemination [32, 33]. Initially, the purveyor oriented 
the OTP director to core CM tenets [34]; specification 
of an observable target behavior, timely provision of tan-
gible reinforcers upon its observance, and withholding 
of reinforcement in its absence. Informed by contextual 
insights into setting needs and resources, the OTP direc-
tor specified: (1) patient population (i.e., new enrollees), 
(2) target behavior (i.e., attendance of weekly counseling 
visits), (3) reinforcers to be provided (i.e., $5 gift cards to 
local vendors, take-home doses), and (4) reinforcement 
system (i.e., a point-based token economy). The hope was 
to enhance engagement of the setting’s 35–40 new enroll-
ees each month, increase their interaction with staff, 
incentivize counseling attendance via affordable reinforc-
ers, and create manageable procedures for existing staff 
to implement. The purveyor devised a reinforcement 
schedule—the rate at which points were to be earned, 
and thresholds at which patients could exchange earned 
points for available reinforcers—incorporating operant 
conditioning principles (i.e., priming, escalation/reset) 
to enrich clinical impact. The design process concluded 
with conjoint review of the intervention by purveyor and 
OTP director, and formal setting approval for its provi-
sional implementation.
Pragmatic trial design feature #2: Voluntary staff 
participation
Substantive role of the OTP director in intervention 
design ensured its consideration of therapy-relevant staff 
attributes like their interest, available time, and profes-
sional capability. Accordingly, the intervention capital-
ized on regularly scheduled contact with new patients, 
direct exposure to therapeutic benefits experienced 
by patients, and concrete procedures intended to pro-
mote reliably skillful staff delivery. Documentation of 
CM-related data at each patient visit (i.e., running point 
total, reinforcers received) in electronic medical records 
offered ongoing means of case-specific fidelity monitor-
ing. Recognizing professional autonomy as a staff value, 
the OTP director afforded individual staff freedom to 
choose if they would participate in the trial, and to what 
extent they attended training and then implemented 
CM on a provisional basis over a predetermined 90-day 
period. As previously-reported [29], 80+ % of staff con-
sented to voluntarily participate and all CM-trained staff 
who had opportunity to implement the intervention did 
so.
Pragmatic trial design feature #3: Serial training outcome 
assessments
Broader therapy training literature documents clinician 
variability in acquisition and maintenance of therapy-
relevant skills, knowledge, and attitudes [35, 36]. Thus, 
longitudinal assessment of a sufficient staff sample was 
needed, with means to account for assessment reactiv-
ity (i.e., ‘practice effects’). Accordingly, serial training 
outcome assessments—prior to, after, and three months 
following training—were conducted with quasi-exper-
imental staff randomization to single vs. multiple base-
line assessment conditions. The primary index in all 
assessments was independently-rated behavioral fidelity 
in a standardized patient (SP) interaction, which mini-
mized setting burden by circumventing the selection 
biases and personal intrusion inherent in observation/
recording of patient sessions. As consistent and conse-
quence-free clinical stimuli, SPs are a validated means 
to produce reliable fidelity estimates for behavior ther-
apy implementation in addiction settings [37]. In each 
assessment, the SP interaction was supplemented by an 
applied CM knowledge instrument [38], multiple-choice 
test of CM principles [39], and adoption readiness scale 
[28]. Efforts to minimize setting burden succeeded inso-
far as all assessments were completed. Resulting data 
sufficiently demonstrated robust longitudinal training 
impacts and absence of assessment reactivity [29].
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Pragmatic trial design feature #4: A post‑training period 
of provisional implementation
The purveyor and OTP director agreed in advance to a 
90-day period following staff training during which CM-
trained staff members had opportunity to implement the 
intervention on a provisional basis with new patients 
assigned to their caseloads. Staff participation in the 
structured CM training was the principal preparatory 
effort, though augmented by a set of four consultative 
planning meetings of the purveyor and five manage-
rial staff for 30 min prior to each staff training sessions. 
Meetings focused on preparatory implementation activi-
ties (i.e., reinforcer purchasing/accounting, electronic 
medical record system modification), and provided the 
purveyor informal means of formative evaluation of set-
ting readiness. These preparatory efforts were concur-
rent to the staff training process and similarly predated 
a 90-day provisional implementation period, after which 
setting management had the option to sustain, amend, or 
discontinue use of the intervention. The specific date of 
onset for this provisional period of implementation was 
left to the OTP director’s discretion (ultimately initiated 
2  weeks after staff training). Summative evaluation of 
implementation experiences occurred at the conclusion 
of this 90-day period, in the context of a group inter-
view with managerial OTP staff wherein their qualitative 
impressions of affordability, compatibility, and sustain-
ability were elicited [30].
Pragmatic trial design feature #5: Broad patient eligibility
The trial sought broad patient eligibility during provi-
sional therapy implementation, with three issues chal-
lenging this effort. The 1st was intervention’s specific 
targeting of new patients, which precluded eligibility of 
existing patients. Second, implementation was only pos-
sible with patients assigned to the caseload of a staff 
member trained to deliver the intervention. Though most 
of the OTP staff participated in CM training, this left a 
minority whose new patients were ineligible. Finally, as 
the OTP’s patient enrollment included admission of a 
subset of individuals on 180-day opioid detoxification, 
the CM intervention was slightly adapted to remove 
take-home medication doses from among available rein-
forcers for these persons. Despite these challenges, the 
CM intervention reached 106 OTP patients during the 
90-day period—exceeding that which was suggested 
for comparison to historical control patients to detect a 
meta-analytic mean effect size (d =  .42) of CM efficacy 
trials [20]. A further encouraging sign for the OTP set-
ting was its emergence from the 90-day period of pro-
visional implementation with report of no persisting or 
unresolved problems of patient eligibility for receipt of 
the CM intervention.
Pragmatic trial design feature #6: Designation of staff 
as local implementation leaders
Provisional therapy implementation was governed auton-
omously by the OTP for several reasons. First, the inter-
vention had clear support of setting leadership given its 
design process. Second, staff training included iterative 
rehearsal of intervention delivery and performance-
based feedback, both suggested methods predictive of 
CM fidelity [40]. Third, all SP interactions were scored 
with a fidelity instrument [41] on which all trained staff 
members exceeded a competency benchmark [42]. With 
the setting poised for provisional implementation with-
out substantial purveyor involvement, the OTP director 
designated two program staff to be local implementation 
leaders—with responsibilities divided into clinical (i.e., 
staff supervision) and administrative (i.e., reinforcer pur-
chasing/accounting) tasks. Both had participated in all 
consultative planning meetings, and were well-positioned 
to address issues arising in provisional implementation. 
Nevertheless, channels of passive purveyor support were 
put in place. One was continual purveyor availability for 
phone/email consultation, utilized sparingly with a hand-
ful of staff-initiated contacts over 90 days. The other was 
creation of an on-site ‘CM training library,’ with master 
copies of all training materials kept in a designated loca-
tion for convenient staff access. The 90-day period of pro-
visional implementation then proceeded at the OTP with 
oversight of CM-trained staff integrated into the setting’s 
supervision-as-usual practices (i.e., semi-weekly individ-
ual case review, weekly staff meetings).
Discussion
Six pragmatic features of the focal hybrid type III imple-
mentation/effectiveness trial have been detailed. Scien-
tific and practical bases underlying the inclusion of each 
feature will now be discussed, along with their perceived 
contribution to post-trial CM sustainment in the setting.
Collaborative intervention design
In many explanatory trials, the purveyor has a clear con-
ceptualization of the focal therapy from the outset that 
precludes its contextualization to the clinical setting. 
Pragmatic trials are apt to approach this differently, as 
local clinical and policy decisions need to account for 
between-setting variance in organizational attributes like 
staffing resources, service structure, and patient census 
characteristics [11]. Among behavior therapies for addic-
tion settings, CM is noted for its capacity for contextual 
adaptation [43]. The conceptual clarity of core CM tenets 
[34] aids this, leaving a set of malleable features (e.g., eli-
gible patients, target behavior, available reinforcers, rein-
forcement system) to then be flexibly defined according 
to setting needs and resources.
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To what extent did the intervention design process con-
tribute to sustainment of CM? A great deal, we believe. 
The purveyor could have instead simply advocated that 
the OTP replicate procedures of Higgins et  al.’s [44] 
escalating voucher or Petry’s [45] prize-based ‘fishbowl’ 
methods that demonstrated prior efficacy. However, the 
OTP director regarded both methods a mismatch for the 
setting’s limited fiscal resources, large patient census, 
and idiographic structure of patient services. A common 
treatment community sentiment is that new practices 
are adopted only if “they don’t conflict with treatments 
already in place” [46]. In addition to matching its fiscal 
resources, the collaborative design process produced 
an intervention that was logistically compatibility with 
existing services—as staff monitored the target behavior, 
tracked points, and delivered earned reinforcers amidst 
usual care in weekly counseling visits. Finally, OTP 
director specification of malleable intervention features 
begot a sense of ownership that otherwise may not have 
developed, prompting emergence of intervention propri-
etorship among setting staff that then guided generally 
positive provisional implementation experiences. There-
after, the OTP director recreated the spirit of the col-
laborative design process by inviting staff feedback about 
potential amendments to malleable intervention features, 
which amplified enthusiasm and commitment among 
setting staff, prior to its formal inclusion in the setting’s 
treatment manual.
Voluntary staff participation
In many explanatory trials, research therapists are hired 
externally—sought by virtue of an affinity for, allegiance 
to, and experience with a focal therapy. Such therapist 
selection serves well the aims of explanatory trials, as do 
common practices of closely-supervised practice cases, 
therapy implementation apart from routine clinic ser-
vices, and expert scrutiny via fidelity review of patient 
sessions. A chief criticism of such procedures for thera-
pist selection, training, and implementation is limited 
external validity with respect to staffing expertise, time, 
and resources in community settings [4]. Related con-
cerns center on typically busier, eclectic clinical practice 
routines of community health providers, and ambiva-
lence commonly held toward adoption of unfamiliar 
behavior therapies [28, 47–49]. The stance in this trial—
that setting staff voluntarily participate in therapy train-
ing and implementation—is consistent with published 
interdisciplinary perspectives that pragmatic trials be 
designed to offer professional development opportunities 
for staff to hone therapeutic skills via direct participation 
in quality improvement efforts [50–52].
To what extent did voluntary staff participation in ther-
apy training and implementation contribute to eventual 
CM sustainment? In our eyes, the contribution was sub-
stantive. Many CM trials, including those attributed with 
demonstrating community effectiveness via NIDA’s Clin-
ical Trials Network [22, 23], rely entirely on external staff-
ing. This translates poorly to the realities that community 
treatment program directors face, and helps explain a 
12 % rate of post-trial CM sustainment among CTN pro-
grams [24]. Community treatment programs must rely 
on existing staff members, who are likely to vary greatly 
in interest and capability to adopt new therapies—and 
among whom mandated training may provoke negative 
reactance. Accordingly, trial recruitment of staff was gov-
erned by optional innovation decisions [53], with individ-
ual OTP staff entrusted to self-determine a participation 
level. An eventual product of this voluntary staff involve-
ment in CM activities was the development of internal 
CM expertise in the setting, on which later decisions 
favoring sustainment of the therapy would rest. This is 
consistent with evidence from prior research wherein 
provisional experience with direct CM delivery predicted 
supportive attitudes toward eventual community-based 
implementation [54, 55]. Coupled with strong managerial 
support for the intervention, provisional implementation 
experiences among CM-trained staff prompted many to 
advocate that nonparticipating staff later undergo train-
ing so that the CM intervention would have broader 
reach within the OTP patient census.
Serial training outcome assessments
In most explanatory trials, there is no report of longitu-
dinal impacts of therapy training, perhaps due to inves-
tigator expectation that procedural fidelity is assured by 
selection of already capable, allegiant research therapists. 
Measurement is typically limited to initial verification of 
skillful delivery in supervised practice cases, and inde-
pendent fidelity rating of therapy sessions subsequently 
conducted during the trial. These research therapists 
are free from many of the complexities and compet-
ing demands inherent in clinical practice [56], instead 
proceeding under fairly idyllic conditions with singu-
lar focus on closely adhering to manualized procedures 
for the identified therapy as delivered to select patients 
for whom it is thought particularly salient. This neglects 
salient dilemmas facing community treatment programs 
about how to develop and maintain internal expertise 
among its clinical staff. Such dilemmas encompass con-
tributing clinician-level issues like time and philosophi-
cal congruence [57] and patient-level challenges such as 
prevalence of polysubstance use disorders and comorbid 
health conditions [58].
To what extent did serial training outcome assessments 
contribute to sustainment of CM? We believe scientific 
and clinical needs were effectively balanced, modeling 
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suggested features of pragmatic trial measurement [59]: 
sufficient data collection, low setting burden, local clini-
cal applicability, and opportunity to show sensitivity to 
change. As reported [29], quasi-experimental staff rand-
omization to single versus multiple baseline assessment 
conditions documented nominal assessment reactivity 
across behavioral, intellectual, and attitudinal training 
outcomes. Notably, it did so without logistical challenges 
and contamination concerns inherent in experimental 
trial designs involving staff randomization to active train-
ing versus waitlist/control conditions. Resulting opportu-
nity to train interested OTP staff as an intact group—and 
assess individual and collective training impacts on CM 
delivery skill, knowledge, and adoption readiness—was 
critical to assure adequate staff preparation for imple-
mentation. A key aspect was post-training documen-
tation of all CM-trained staff exceeding a competency 
benchmark for delivery skill [42]. Absence of unresolved 
problems in provisional implementation, paired with trial 
documentation of durable training gains over 90  days, 
heightened setting confidence for prospects of post-trial 
sustainment.
A post‑training period of provisional implementation
In most explanatory trials, assessment of therapy imple-
mentation serves strictly scientific purposes. Available 
data are limited to fidelity ratings of therapy sessions 
by externally-hired, trained, and supervised research 
therapists delivering a focal therapy and/or compara-
tive therapy approach. Statistical documentation that 
such ratings evidence treatment integrity (i.e., delivery 
as purveyor intended) and discriminability (i.e., deliv-
ery distinct from its comparator) are key scientific aims 
[60], and this understandably encompasses evaluation of 
therapy implementation in many trials. An unfortunate 
consequence is that issues complicating real-world ther-
apy implementation are left unaddressed. Broadly, these 
relate to implementation costs (i.e., staff time required 
for therapy training and implementation, clinical super-
vision, necessary therapy materials or technology), con-
textual compatibility with setting structure (i.e., other 
clinical services, records systems), and observed penetra-
tion or reach (i.e., rates of staff adoption and/or patient 
exposure) in a setting [31, 61]. Absent serious consid-
eration of such issues, sustainment of an empirically-
supported behavior therapy for any meaningful period is 
difficult to imagine.
Did inclusion of an initial period during which CM-
trained setting staff implemented the CM intervention 
with their patients on a provisional basis contribute to 
its eventual sustainment? Our answer is yes, eventually. 
Onset of this 90-day period shortly after staff training 
allowed provisional implementation experiences to occur 
as staff training gains were fresh. The 90-day duration was 
informed by published recommendation of conserva-
tive sampling and analytic methods, given greater patient 
heterogeneity encountered in pragmatic trials [62]. This 
length of time provided sufficient staff and patient expo-
sure to CM, which informed discussion of possible inter-
vention amendments amongst a designated committee 
of OTP staff. Setting decision about sustainment was ini-
tially deferred until results of a chart-based comparison 
of CM-exposed versus historical control patients were 
known. As had been true throughout the trial, purveyor 
citation of reliable therapeutic effects observed in extant 
CM literature conducted in addiction treatment set-
tings was met with a familiar refrain that “none of those 
studies were conducted here” [63]. Upon later receipt 
of documentation of site-specific clinical effectiveness 
(d  =  .45–.53, [29]), the setting formally committed to 
sustain the CM intervention among routine service pro-
visions, and required exposure of all untrained and pro-
spectively-hired staff to the CM training curriculum.
Broad patient eligibility
Explanatory trials use inclusion/exclusion criteria to 
select persons from a larger patient population for whom 
a focal therapy is thought particularly relevant. In CM 
trials in addiction settings, this often restricts recruit-
ment to those with diagnosis or recent evidence of a 
single substance of abuse and absent medical or psychi-
atric comorbidity. This has clear advantages, as titration 
of treatment-seeking populations to those uniformly 
presenting with compartmentalized therapeutic needs 
simplifies both formulation and confirmation of hypoth-
esized therapy effects. Of course, this significantly limits 
generalizability of resulting findings, as polysubstance 
use and multivariate health challenges are commonplace 
among enrollees at addiction settings [64, 65]. Selective 
therapy application, particularly when offering tangi-
ble rewards as contemporary CM approaches do, may 
spur reticence from staff and patients about issues of 
social justice. The more selectively applicable a therapy is 
framed to be, the lesser opportunity community settings 
and their staff have to witness relative advantages, com-
patibility, simplicity, trialability, and observability—all 
hallmark attributes of innovative practices that are widely 
adopted [53].
What impact did broad application of the intervention 
among OTP enrollees have on CM sustainment? Dur-
ing the 90-day period of immediate implementation on 
a provisional basis, broad patient eligibility facilitated 
timely accrual of a sufficient sample of CM-exposed 
patients to establish site-specific clinical effectiveness and 
100 % penetration among CM-trained staff. Thus, quali-
tative impressions of its affordability and compatibility 
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formally voiced by managerial staff at trial conclusion 
reflected direct experiences of most staff. With respect 
to the eventual sustainment of CM implementation at 
the OPT, broad application of the intervention among 
OTP enrollees was thought to strengthen perceived rel-
evance of supporting evidence for setting-specific clini-
cal effectiveness. An additional factor cementing the 
post-trial setting decision for CM sustainment was the 
vocal positive feedback about the intervention that staff 
reported receiving from their CM-exposed patients [29]. 
Broad patient eligibility enabled a greater proportion of 
new OTP enrollees to serve as sources of this informal 
feedback.
Designation of staff as local implementation leaders
In explanatory trials, therapy implementation is closely 
monitored to ensure what occurs is as the purveyor 
intends. This is understandable, given a principal aim of 
such trials to confirm a therapy’s hypothesized effects. 
Pragmatic trials, in contrast, seek to balance competing 
needs of a clinical setting: (1) availability of purveyor sup-
port in initial therapy implementation, and (2) organi-
zational autonomy so that internal expertise is culled to 
support independent sustainment. As Johnson et al. [31] 
suggest, implementation is facilitated by therapy inte-
gration into the flow of existing clinical practices. Thus, 
it is critical that a purveyor be available to support such 
efforts but without unnecessary involvement in their 
conduct. This is consistent with phased models of ther-
apy implementation [66, 67], wherein removal of pur-
veyor support and self-governed therapy sustainment by 
the clinical setting are intended endpoints.
Did designation of two OTP staff as local implemen-
tation leaders spur CM sustainment? One local imple-
mentation leader oversaw staff via supervision-as-usual 
practices at the OTP for which (commensurate with 
resources available in many clinical settings) time-inten-
sive use of observational fidelity systems is impractical. 
This was sufficient to prevent the deterioration of ini-
tial training gains often observed after therapy training 
[68, 69], and to document therapeutic impacts similar 
to those of trials where community staff received active 
purveyor supervision [70–72]. The 2nd local implemen-
tation leader coordinated administrative procedures, for 
which the OTP emerged from provisional implementa-
tion absent unresolved issues. These collective actions 
contributed to setting impressions of intervention afford-
ability and compatibility. Had local implementation leader 
voiced strong concern, evidenced inability to keep up with 
duties, or otherwise demonstrated need for active pur-
veyor support during provisional implementation, setting 
enthusiasm for CM sustainment would surely have atten-
uated. Instead, provisional implementation experiences 
maintained, if not strengthened, enthusiasm for CM in 
the setting. Notably, supervision-as-usual practices per-
sisted after the trial, with previously-untrained staff later 
exposed to the CM training curricula. Administrative 
procedures were largely maintained post-trial, with effort 
to improve efficiency of tracking systems and manage 
interdepartmental coordination amidst a two-year period 
of organizational growth. Further, local implementation 
leaders continued to serve as repositories for CM-relevant 
feedback from staff and patients.
Conclusions
In this retrospective trial design paper, the contribution 
of pragmatic design features of a hybrid type III imple-
mentation/effectiveness trial to the eventual two-year 
sustainment of a CM intervention is described. Prag-
matic design considerations had implications for how: 
(1) the intervention was designed, (2) OTP staff were 
recruited for trial involvement, (3) impacts of training 
on staff implementation outcomes were documented, 
(4) provisional implementation and resulting clinical 
effectiveness were assessed, (5) broad eligibility among a 
patient population occurred, and (6) localized staff lead-
ership was culled to support setting autonomy in estab-
lishing sustainable implementation procedures. Though 
the single-site nature of this trial may obscure complexi-
ties encountered in interagency therapy dissemination 
[73], it is hoped this description and discussion of prag-
matic design features may spark ideas for future transla-
tional work concerning empirically-supported behavior 
therapies in community addiction settings.
Additional systemic processes enacted by the OTP in 
its two-year CM sustainment bear mentioning. One was 
iterative gathering of CM-related feedback from stake-
holders, including clinical staff across service lines and 
(when possible) patients. As a result, creative uses of 
positive reinforcement permeated staff discussions and 
prompted later creation of other CM programming in 
this and two other newly-opened clinics governed by the 
treatment organization. Likewise, input was elicited from 
administrative staff to refine tracking systems for fiscal 
aspects of all CM programming. A 2nd systemic process 
involved staffing re-organization, with resources dedi-
cated to create a ‘CM specialist’ position to coordinate 
sustainment of the focal intervention and introduction of 
other CM programming across OTP service lines. A 3rd 
systemic process involved a philosophical shift away from 
voluntary staff involvement in training/implementation 
activities [noted as examples of Rogers’ [53] optional 
innovation-decisions during the trial]. A necessary post-
trial shift to authority innovation-decisions (i.e., system-
wide adoption determined by those in authority) [53] 
mirrored that predictive of expedient change in complex 
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systems like healthcare organizations. To prevent poten-
tial circumvention by uninterested staff members, inter-
nal communication from setting leadership highlighted 
the voluminous empirical support for CM and setting-
specific evidence of the focal intervention’s clinical util-
ity. Collectively, post-trial systemic processes enabled the 
OTP to apply CM principles to a breadth of setting goals 
and patient needs, and it remains poised to effectively 
respond to future challenges as they emerge.
To conclude, we hope this discussion reinforces the 
earlier sentiments of Schwartz and Lellouch [10], Flay 
[13], Rothwell [4], and others about the value of design-
ing trials with sufficient attention to external validity. In 
looking back to this single-site trial to dissect its design 
features and the decisions underlying their inclusion, the 
intent is not to offer up a specific blueprint for other trial-
ists to follow. Rather, it is hoped this work may prompt 
thoughtful and collaborative discussion about the design 
and conduct of future behavior therapy trials amongst 
therapy purveyors and community treatment settings 
with whom they partner. Such discussions enhance the 
likelihood of mutually-beneficial endeavors, for which 
resulting findings can then substantively guide local 
clinical and policy decisions about health services the 
public receives. In this example, a hybrid type III imple-
mentation/effectiveness trial predated sustainment of an 
empirically-supported CM intervention by an OTP. This 
is a reflection of efforts to harmonize rigor in scientific 
aims with appreciation for the fluidity and practicali-
ties inherent in clinical practice. Insofar as CM remains 
firmly embedded in this addiction treatment organiza-
tion’s routine service provisions, those collective efforts 
contributed to music that continues to play on.
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